Corning’s Specialty Glass With Micromorph Technology Delivers 11.9% Efficiency

Corning Photovoltaic Glass Technologies and Oerlikon Solar have declared the 11.9% stable solar conversion competence achieved in a research -size silicon tandem photovoltaic cell. The efficiency was checked by utilizing an exclusive combination of Micromorph technology of Oerlikon solar and the specialty thin glass of Corning without any antireflective coating. The test results were confirmed by the National Renewable Energy Laboratory (NREL) of United States.

The solar industry was always worried about the increased conversion efficiency to improve the energy conversion rate into current. The latest Micromorph- tandem technology of Oerlikon made notable progression in thin film photovoltaics, a fast growing sector of the solar energy industry. The developed photovoltaic research blends with the superior light absorbing capabilities of Corning’s specialty glass and the patented Micromorph technology of Oerlikon solar that utilizes a zinc oxide low pressure chemical vapor deposition (LPCVD) contact at the front for improved energy absorption efficiency.

Dr. Gary Calabrese, Vice President of Science and Technology and Director of Corning Photovoltaic Glass Technologies, expressed his happiness about the achieved landmark and the coordination between Oerlikon Solar and Corning. He added that he is optimistic about the opportunities created for the PV industry by the new advancement and hoped that the united efforts of the two companies are expected to accomplish improved efficiencies in energy conversion.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.